TFB 15: Die Bedeutung des Komplementspaltproduktes C3a als diagnostischer Frühmarker in der Sepsis

本项目的目的是将有关炎症介质C3a作为脓毒症患者诊断标志物的重要性的结果转化为临床应用。这些数据是在合作研究中心244《慢性炎症》中获得的。为了验证初步结果，进行了一项前瞻性的多中心研究，来自慕尼黑-戈恩、曼海姆、海德堡、马格德堡和汉诺威的八个不同的外科、内科和麻醉科重症监护病房参与其中。为了关注该综合征的最初阶段，本研究对不同的感染高危人群进行了调查。除了分析补体系统的激活，还研究了炎症介质IL-6和降钙素原的释放。最关键的问题是，血液中不同免疫学参数的测定是否可以及早诊断脓毒症，即在临床症状出现之前。工业合作伙伴Biognosis生产了一种新颖的自动化C3a床边分析方法，将在参与的重症监护病房进行评估。

The aim of this project is to transfer the results concerning the importance of the inflammatory mediator C3a as a diagnostic marker in septic patients into a clinical application. These data were obtained in the collaborative research centre 244 "Chronic Inflammation". To validate the preliminary results, a prospective multicenter study is performed, in which eight different surgical, internal and anesthesiologic intensive care units from Munich-Goßhadern, Mannheim, Heidelberg, Magdeburg and Hannover participate. To focus on the very beginning of the syndrome, different patient groups with a high risk to develop sepsis are investigated in this study. In addition to the analysis of the activation of the complement system the release of the inflammatory mediators IL-6 and procalcitonin is investigated. The most critical question is whether the determination of the different immunological parameters in blood allow to diagnose sepsis early i.e. before clinical signs develop. The industrial partner Biognosis produced a novel, automated C3a bedside-assay which will be evaluated in the participating intensive care units.